IPSEN Group Follow / Connect - Business Profile & Social Media Wall / Press Room - Pharma / BioTech / Nutrition

IPSEN Group Company Profile & Social Media Wall Press Room - Press Releases

Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

	Company Name:	IPSEN Group
	Trading Symbol(s):	[Euronext: IPN; ADR: IPSEY]
	Contact:	Press Office - IPSEN.com
	Address:	Confidential
	City:	Boulogne Billancourt
	Zip code:	92100
	STATE / Prov.:	Hauts-de-Seine
	Country:	France
	Primary Industry:	Pharma / BioTech / Nutrition
	PR Agency:	No

Your Company Advertising Here!
Showing along with this industry
- Learn more...

Latest Articles:
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) - [ Pharma / BioTech / Nutrition ]
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva - [ Pharma / BioTech / Nutrition ]
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics - [ Pharma / BioTech / Nutrition ]
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders - [ Pharma / BioTech / Nutrition ]
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001 - [ Pharma / BioTech / Nutrition ]
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease - [ Pharma / BioTech / Nutrition ]
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression - [ Pharma / BioTech / Nutrition ]
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer - [ Pharma / BioTech / Nutrition ]
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® - [ Pharma / BioTech / Nutrition ]
Ipsen Announces New Data from the Phase II CLARINET FORTE Study - [ Pharma / BioTech / Nutrition ]
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress - [ Pharma / BioTech / Nutrition ]
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress - [ Pharma / BioTech / Nutrition ]
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP) - [ Pharma / BioTech / Nutrition ]
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting - [ Pharma / BioTech / Nutrition ]
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer - [ Pharma / BioTech / Nutrition ]
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer - [ Pharma / BioTech / Nutrition ]
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society - [ Pharma / BioTech / Nutrition ]
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program - [ Pharma / BioTech / Nutrition ]
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® - [ Pharma / BioTech / Nutrition ]
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs - [ Pharma / BioTech / Nutrition ]
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria - [ Pharma / BioTech / Nutrition ]
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy - [ Pharma / BioTech / Nutrition ]
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019 - [ Pharma / BioTech / Nutrition ]
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years - [ Pharma / BioTech / Nutrition ]
Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference - [ Medical Services / Equipment ]

« Previous Page

Next Page »

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business

ó See your Ad Here! ó

PREMIUM Members

ó See your Logo Here! ó